Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001144204-12-039468
Filing Date
2012-07-13
Accepted
2012-07-13 18:18:39
Documents
1
Period of Report
2012-07-13

Document Format Files

Seq Description Document Type Size
1 form324611_20120713061804-.html 3  
1 form324611_20120713061804-.xml 3 4625
  Complete submission text file 0001144204-12-039468.txt   6319
Mailing Address 128 SPRING STREET SUITE 520 LEXINGTON MA 02421
Business Address 128 SPRING STREET SUITE 520 LEXINGTON MA 02421 (781) 357-9900
SYNAGEVA BIOPHARMA CORP (Issuer) CIK: 0000911326 (see all company filings)

EIN.: 561808663 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 667 MADISON AVE. 21ST FLOOR NEW YORK NY 10065
Business Address 667 MADISON AVE. 21ST FLOOR NEW YORK NY 10065 212-339-5600
Baker Biotech Fund II (A), L.P. (Reporting) CIK: 0001551130 (see all company filings)

State of Incorp.: DE | Fiscal Year End: 1231
Type: 3 | Act: 34 | File No.: 000-23155 | Film No.: 12962518